{"entity":{"id":"paper-checkmate-915-j-immunother-cancer-2025","kind":"paper","name":"Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915","aka":[],"tldr":"Published report from the CheckMate 915 trial registered as NCT03068455, in Journal for ImmunoTherapy of Cancer (2025), chosen as the most cited paper whose own text cites the registry id.","summary":"Purpose: CheckMate 915 (NCT03068455) compared adjuvant nivolumab monotherapy versus combination nivolumab+ipilimumab in patients with resected stage III/IV melanoma. This exploratory analysis was performed to identify biomarkers that correlate with benefit from adjuvant immunotherapy.\n\nPatients and methods: 1,844 patients received nivolumab 480 mg every 4 weeks or nivolumab 240 mg every 2 weeks with ipilimumab 1 mg/kg every 6 weeks. Tumor and peripheral biomarkers were evaluated, including tumor-informed circulating tumor DNA (ctDNA) at postresection baseline and on-treatment, for their association with recurrence-free survival and distant metastases-free survival.\n\nResults: Biomarker analyses were conducted in 60-96% of the intention-to-treat population. ctDNA positivity at baseline (seen in 16.2% of patients) and on-treatment was associated with higher risk of recurrence than ctDNA negativity (HR, 1.97; 95% CI, 1.57 to 2.46), with a high specificity (87%) and modest sensitivity (39%). ctDNA status, tumor mutational burden (TMB) status (TMB < or ≥350 mutations/tumor) and interferon gamma-RNA signature score (< or ≥median) evaluated together, as well as ctDNA status with tumor CD8 or cell programmed death ligand 1 expression, were more predictive of survival than ctDNA alone. Tumor bulk RNA-seq expression patterns identified gene expression at baseline associated with recurrence.\n\nConclusions: This study represents the largest assessment of ctDNA and other baseline tumor and peripheral biomarkers for predicting recurrence-free survival in patients with resected melanoma receiving adjuvant immunotherapy. ctDNA alone and in combination with more established biomarkers predicted recurrence-free and distant metastasis-free survival and has potential utility for assessing and monitoring the risk of recurrence in patients with resected melanoma treated with immunotherapy in the adjuvant setting.\n\nTrial registration number: NCT03068455.\n\nIndexed on Europe PMC as PubMed record 40645660 (DOI 10.1136/jitc-2025-012034). Its abstract cites the registry id NCT03068455, which is how it was matched to this trial; no figure has been checked by an editor.","asOf":"2026-09-22","links":[{"label":"J Immunother Cancer 2025","url":"https://doi.org/10.1136/jitc-2025-012034"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/40645660/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/40645660"},{"label":"ClinicalTrials.gov NCT03068455","url":"https://clinicaltrials.gov/study/NCT03068455"}],"tags":["europepmc-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["checkmate-915"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jitc"],"dependsOn":[],"notes":[],"journal":"Journal for ImmunoTherapy of Cancer","year":2025,"doi":"10.1136/jitc-2025-012034","pmid":"40645660","authors":"Long GV, Tang H, Desai K, et al.","paperType":"rct","findings":[],"whatItMeans":"This is the paper Europe PMC returns for registry id NCT03068455 with the most citations, so it is the natural first reading for anyone following the CheckMate 915 trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.","caveats":["Matched to the trial by the registry id cited in the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper."]},"route":"/key-papers/paper-checkmate-915-j-immunother-cancer-2025/","neighbours":{"trial":[{"id":"checkmate-915","kind":"trial","name":"CheckMate 915","route":"/trials/checkmate-915/"}],"journal":[{"id":"jitc","kind":"journal","name":"Journal for ImmunoTherapy of Cancer","route":"/journals/jitc/"}]}}